Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy

International Journal of Radiation Oncology*Biology*Physics(2021)10.1016/j.ijrobp.2021.06.038Source: DataRank Database

Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy is a research paper published in International Journal of Radiation Oncology*Biology*Physics (2021). On theSindex it has a DataRank of 0. It has been cited 53 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access53 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 3.16)OA: greenTopics (38)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Timothy J. Robinson ORCID,Austin J. Sim ORCID,Xuefeng Wang ORCID,Biwei Cao ORCID,Julio C. Chávez ORCID

Live enrichment

PubMed:34242714 PMC:PMC9791939 OpenAlex:https://openalex.org/W3179559390

NCI NIH HHS

Grant: P30 CA076292

National Institutes of Health

Grant: K23-CA201594

National Institutes of Health

Grant: P30-CA076292

NCI NIH HHS

Grant: K23 CA201594

National Institutes of Health

Grant: 1K23CA201594-01

Breaking immune tolerance to Survivin in Multiple Myeloma

National Institutes of Health

Grant: 3P30CA076292-24S2

Moffitt Cancer Center Support Grant

National Cancer Institute

FWCI

3.16

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9791939

journalhttps://doi.org/10.1016/j.ijrobp.2021.06.038

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34242714

https://dx.doi.org/10.1016/j.ijrobp.2021.06.038

Fields of Study

CAR-T cell therapy researchLymphoma Diagnosis and TreatmentCutaneous lymphoproliferative disorders research03 medical and health sciences0302 clinical medicineCell- and Tissue-Based TherapyHumansImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseNeoplasm Recurrence, LocalReceptors, Chimeric AntigenRetrospective Studies

MeSH Terms

Receptors, Chimeric AntigenHumansNeoplasm Recurrence, LocalRetrospective StudiesImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseCell- and Tissue-Based Therapy

Keywords

Chimeric antigen receptorRefractory (planetary science)AntigenMedicineReceptorImmunologyT cellCancer researchOncologyInternal medicineBiologyImmune systemReceptors, Chimeric AntigenCell- and Tissue-Based TherapyHumansLymphoma, Large B-Cell, DiffuseNeoplasm Recurrence, LocalImmunotherapy, AdoptiveRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good health

Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy

FAIR Checklist

Authors (16)

Funding (7 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)